RxDoctor Payments Data

John Nelson, MD

Family Medicine · Asheville, NCNPI 1528047248

Payments from drug & device makers

$533in general payments, 2019–2025

Across 12 payments — averaging $44.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$128
  • Bayer$117
  • Mylan Specialty L.p.$114
  • Johnson & Johnson$77
  • Sunovion Pharmaceuticals Inc.$73
  • Astellas Pharma US Inc$13
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$533100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$533 in reported general payments places this provider in the 60th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$445,341
Medicare patients
663
Services billed
4,908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban578$223,057
Humira(Cf) PenAdalimumab16$117,756
IngrezzaValbenazine Tosylate11$71,260
LinzessLinaclotide79$45,807
JanuviaSitagliptin Phosphate69$33,029
XareltoRivaroxaban64$29,497
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$29,181
TrulicityDulaglutide68$28,856
OzempicSemaglutide24$25,679
TradjentaLinagliptin74$25,021
EntrestoSacubitril/Valsartan77$24,395
Lupron DepotLeuprolide Acetate11$24,075
JardianceEmpagliflozin56$23,480
RexultiBrexpiprazole23$22,299
IsentressRaltegravir Potassium12$22,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$128$71,26011 claims
Johnson & JohnsonXarelto$77$29,49764 claims
Avanir Pharmaceuticals, Inc.Nuedexta$12$16,51618 claims
Astellas Pharma US IncMyrbetriq$13$15,19343 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →